OTC:CC - Ocumetics Achieves Clinical Milestones; Poised for Value-Defining First-in-Human Lens Implantations
(TheNewswire)
Calgary, Alberta – TheNewswire - August 12, 2025 -Ocumetics Technology Corp . (“Ocumetics” or the “Company”)(TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in advancedophthalmic technology, is pleased to announce the successfulcompletion of key clinical milestones and to share an update on theanticipated first-in-human (“FIH”) surgeries.
“This is a moment our entire team has been workingtoward for years,” said Dean Burns, CEO of Ocumetics. “Everymilestone we’ve achieved in recent weeks reflects the dedication,expertise, and sheer determination of our people and partners. We’renow just a few days away from transforming the future of visioncorrection with the first implantation of our groundbreakingaccommodating intraocular lens. I couldn’t be prouder of what ourteam has accomplished.”
Over the past several weeks, Ocumetics has madesignificant clinical progress:
June 26, 2025 - Virtual site initiation of the clinicalpartner site in Mexico City completed, confirming readiness to conductthe FIH clinical study.
July 9, 2025 - Completion of clinical study protocoltraining for the clinical team in Mexico City.
July 30, 2025 - Receipt of verbal ethics committeeapproval for the study protocol, validating the site’s compliancewith the highest international standards for patient safety,scientific integrity, and ethical principles.
August 5, 2025 - Commencement of patient recruitment atthe Mexico City clinical site.
August 8, 2025 - Implantation of control lensescompleted.
Upcoming clinical activities include:
Final site initiation and surgeon training immediatelyprior to the FIH lens implantations
First-in-human implantation of the Ocumeticsaccommodating intraocular lens
Daily, weekly, and monthly patient progressmonitoring
Planning for Group 2 surgeries, anticipated in Q12026
Given the imminent FIH surgeries, the Company haselected not to proceed with the second tranche of the privateplacement announced on June 4, 2025. Ocumetics successfullycompleted tranche 1 of the financing, raising $1,124,362 through theissuance of 3,212,462 units. The Company paid fees of $68,610 andissued 196,029 agent’s warrants to Numus Capital Corp. for itsassistance on the financing. The Company intends to introduce afinancing with revised terms following the completion of thesehistoric procedures.
About Ocumetics
Ocumetics Technology Corp. ( TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO)is a Canadian research and product development company that is dedicated to developing advanced visioncorrection solutions that enhance the quality of life for patients. Through innovative research and development, Ocumetics aims to transform the field of ophthalmology withstate-of-the-art intraocular lenses and other vision-enhancingtechnologies.
Ocumetics is in the preclinical study phase of agame-changing technology for the ophthalmic industry. Ocumetics hasdeveloped an intraocular lens that fits within the natural lenscompartment of the eye, potentially to eliminate the need forcorrective lenses. It is designed to allow the eye’s naturalmuscle activity to shift focus from distance to near, providing clearvision at all distances without the help of glasses or contact lenses.
FOR FURTHER INFORMATION, PLEASECONTACT:
Dean Burns Roger Jewett
President and Chief Executive Officer ChiefFinancial Officer
(817) 874-7564 roger.jewett@ocumetics.com
Neither the TSXVenture Exchange nor its Regulation Services Provider (as that term isdefined in the policies of the TSX Venture Exchange) acceptsresponsibility for the adequacy or accuracy of this release.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKINGINFORMATION: This news release includes certain “forward-lookingstatements” under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to,statements with respect to the commencement, timing and scope of theresearch and development to be conducted by the Corporation mentionedabove. Forward-looking statements are necessarily based upon anumber of estimates and assumptions that, while considered reasonable,are subject to known and unknown risks, uncertainties, and otherfactors which may cause the actual results and future events to differmaterially from those expressed or implied by such forward-lookingstatements. Such factors include but are not limited to: operationalmatters, historical trends, current conditions and expected futuredevelopments, access to financing as well as other considerations thatare believed to be appropriate in the circumstances. There can be noassurance that such statements will prove to be accurate, as actualresults and future events could differ materially from thoseanticipated in such statements. Accordingly, readers should not placeundue reliance on forward-looking statements. The Corporationdisclaims any intention or obligation to update or revise anyforward-looking statements, whether as a result of new information,future events or otherwise, except as required by law.
Copyright (c) 2025 TheNewswire - All rights reserved.